InvestorsHub Logo
Followers 840
Posts 120475
Boards Moderated 18
Alias Born 09/05/2002

Re: None

Tuesday, 09/11/2018 1:09:01 PM

Tuesday, September 11, 2018 1:09:01 PM

Post# of 6446
Bavencio/Inlyta shows statsig-better PFS than Sutent monotherapy in first-line RCC for both PD-L1≥1% subgroup (primary endpt) and the entire patient pool (secondary endpt):

#msg-143489850

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PFE News